ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,616.84
      0.00%
      US Tech 100
      18,957.60
      -0.29%
      Dow Jones
      41,240.52
      0.00%
      Brent Oil
      79.815
      -0.56%
      Bitcoin
      62,424.07
      -0.73%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Vertex Pharmaceuticals Inc (VRTX)

      7. Vertex Pharmaceuticals Inc (VRTX) News

      VRTX

      Vertex Pharmaceuticals (VRTX)

      Vertex Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:VRTX
      DateTimeSourceHeadlineSymbolCompany
      2:03PMiHub NewswireFeaturedELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET
      08/22/20248:00AMBusiness WireVertex to Participate in Upcoming September Investor ConferencesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/16/20244:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/12/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/08/20244:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/08/202411:47AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/07/20247:12PMBusiness WireVertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in EnglandNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/07/20249:52AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/02/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/02/20244:03PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRTXVertex Pharmaceuticals Inc
      08/01/20244:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/01/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/01/20244:01PMBusiness WireVertex Reports Second Quarter 2024 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/01/20243:34PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/30/20243:25PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/30/20241:10PMBusiness WireVertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute PainNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/25/20244:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/24/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/24/202412:27PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/22/20241:16PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/17/20244:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/15/20249:00AMPR Newswire (Canada)Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare MutationsNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/15/20249:00AMPR Newswire (Canada)Santé Canada autorise la commercialisation de TRIKAFTA(MD) (éléxacaftor/tézacaftor/ivacaftor et ivacaftor) chez les personnes atteintes de fibrose kystique âgées de 2 ans et plus présentant certaines mutations raresNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/12/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/10/202410:27AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/02/20248:33AMBusiness WireVertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/01/20244:05PMBusiness WireVertex to Announce Second Quarter 2024 Financial Results on August 1NASDAQ:VRTXVertex Pharmaceuticals Inc
      06/21/20243:45PMBusiness WireVertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific SessionsNASDAQ:VRTXVertex Pharmaceuticals Inc
      06/20/20247:15AMBusiness WireVertex Announces Extended Long-Term Reimbursement Agreement with NHS England for Access to Cystic Fibrosis Medicines KAFTRIO®, SYMKEVI® and ORKAMBI®NASDAQ:VRTXVertex Pharmaceuticals Inc
      06/14/20243:03AMBusiness WireVertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) CongressNASDAQ:VRTXVertex Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:VRTX